Daiichi Sankyo

2023’s biggest launches: the story so far
EP Vantage
Fri, 05/12/23 - 10:19 am
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
A blockbuster year could be building
EP Vantage
Wed, 05/10/23 - 09:55 am
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market
Fierce Biotech
Fri, 04/21/23 - 10:08 am
Daiichi Sankyo
Astellas
Novartis
quizartinib
FDA
blood cancer
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
Mon, 04/3/23 - 09:41 am
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
Esperion, Daiichi Sankyo milestone payment feud heats up with new lawsuit
Fierce Pharma
Tue, 03/28/23 - 10:57 pm
Esperion Therapeutics
Daiichi Sankyo
Nexletol
SEC
Zymeworks, Daiichi end $293M bispecific collab after 6 unfruitful years
Fierce Biotech
Mon, 03/20/23 - 09:56 am
Zymeworks
Daiichi Sankyo
immuno-oncology
biobucks
Daiichi torches Esperion’s Nexletol milestone promises
EP Vantage
Fri, 03/17/23 - 10:10 am
Daiichi Sankyo
Esperion Therapeutics
Nexletol
AstraZeneca, Daiichi Sankyo tease new Enhertu data — but details remain under wraps
Endpoints
Mon, 03/6/23 - 11:27 pm
AstraZeneca
Daiichi Sankyo
Enhertu
clinical trials
Daiichi Sankyo gets US patent office to restart review of Seagen patent
Endpoints
Mon, 02/20/23 - 12:40 pm
Daiichi Sankyo
Seagen
PTO
patents
Daiichi Sankyo to build Japan's first mRNA vaccine manufacturing facility — report
Endpoints
Wed, 02/8/23 - 10:58 pm
Daiichi Sankyo
Japan
MRNA
vaccines
drug manufacturing
The first big test for the son of Enhertu
EP Vantage
Fri, 01/20/23 - 10:17 am
Daiichi Sankyo
Enhertu
datopotamab deruxtecan
clinical trials
Biopharma's stock market winners of 2022 revealed
EP Vantage
Wed, 01/18/23 - 09:46 am
pharma stocks
Merck
Eli Lilly
AbbVie
Daiichi Sankyo
Vertex Pharmaceuticals
Takeda
Sarepta Therapeutics
Halozyme
Horizon Therapeutics
10 clinical trials to watch in the first half of 2023
BioPharma Dive
Tue, 01/3/23 - 10:57 am
clinical trials
Alzheimer's disease
obesity
Huntington's disease
M&A
AstraZeneca
Daiichi Sankyo
Nimbus Therapeutics
Takeda
Eli Lilly
Sanofi
Regeneron
Moderna Therapeutics
Gilead Sciences
Pfizer
Roivant
Alnylam
uniQure
Biotech’s key upcoming clinical results
EP Vantage
Tue, 12/20/22 - 10:27 am
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Big pharma’s new year catalysts
EP Vantage
Mon, 12/19/22 - 11:05 am
AstraZeneca
Daiichi Sankyo
Pfizer
Roche
CSL
uniQure
Novo Nordisk
Eli Lilly
AstraZeneca-Daiichi Sankyo’s therapy shows response in breast cancer trials
Clinical Trials Arena
Mon, 12/12/22 - 10:26 am
AstraZeneca
Daiichi Sankyo
clinical trials
datopotamab deruxtecan
metastatic triple-negative breast cancer
breast cancer
SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla
Fierce Pharma
Fri, 12/9/22 - 10:54 am
SABCS
AstraZeneca
Enhertu
breast cancer
Daiichi Sankyo
Roche
Kadcyla
Chasing Gilead, AstraZeneca-Daiichi lay down phase 2 breast cancer data for antibody-drug conjugate
Fierce Biotech
Fri, 12/9/22 - 10:46 am
AstraZeneca
Daiichi Sankyo
breast cancer
antibody-drug conjugate
clinical trials
Gilead Sciences
Daiichi Sankyo To Transfer Yescarta Marketing Authorization In Japan To Gilead Sciences
NASDAQ.com
Thu, 12/8/22 - 10:03 am
Daiichi Sankyo
Gilead Sciences
Yescarta
Japan
The problem with Her2-low testing
EP Vantage
Mon, 11/28/22 - 07:34 pm
AstraZeneca
Daiichi Sankyo
Enhertu
breast cancer
diagnostics
HER2-low breast cancer

Pages